Mochida Pharmaceutical takes 20% stake in And Pharma, forms strategic alliance

Mochida Pharmaceutical Co., Ltd. announced on September 22, 2025, its decision to acquire a 20% stake in And Pharma Co., Ltd. This will make And Pharma an equity-method affiliate, involving underwriting a third-party allocation of shares and acquiring shares from Godo Kaisha JEH. The total acquisition cost for common shares of And Pharma will be JPY 16,199 million for 197,818,534 shares.

This strategic move aligns with Mochida's "Vision for 2031" and its 25-27 Medium-term Management Plan, aiming to accelerate growth through enhanced profitability and sustained investment in growth areas. The collaboration with And Pharma, a pure holding company with subsidiaries Nichi-Iko, Kyowa Pharmaceutical Industry, and T's Pharma, is expected to create synergies in biosimilar development, manufacturing, and stable supply. Itochu Corporation will also acquire a stake in And Pharma, joining Mochida in its management and further strengthening And Pharma’s business foundation.

The transaction is scheduled for completion with the share transfer and subscription to the third-party allotment by October 1, 2025. Mochida expects this acquisition to contribute to its performance through equity method investment income and enhance corporate value. Further details on the impact on its consolidated earnings forecast for the fiscal year ending March 2026 are currently under review.